Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
University of California, San Francisco
University of California, San Francisco
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Travera Inc
Eli Lilly and Company
Nammi Therapeutics Inc
National Cancer Institute (NCI)
Beijing Biotech
Jazz Pharmaceuticals
Bayer
AstraZeneca
Pfizer
National Institutes of Health Clinical Center (CC)
Actuate Therapeutics Inc.
AstraZeneca
Memorial Sloan Kettering Cancer Center
Imperial College London
City of Hope Medical Center
Eli Lilly and Company
Filamon LTD
Origin Sciences
AstraZeneca
University of Michigan Rogel Cancer Center
Hoffmann-La Roche
Rutgers, The State University of New Jersey
UMC Utrecht
Aveni Foundation
Psyence Australia Pty Ltd
ViroMissile, Inc.
National Taiwan University Hospital
Dana-Farber Cancer Institute
Duke University
AstraZeneca
Tasca Therapeutics
Essen Biotech
MBrace Therapeutics
Azienda Ospedaliero-Universitaria di Parma
A2 Biotherapeutics Inc.
Angiex, Inc.
Poseida Therapeutics, Inc.
MacroGenics
Unity Health Toronto
City of Hope Medical Center
xCures
Daiichi Sankyo
University of Nebraska
Takeda
Cue Biopharma
Boehringer Ingelheim